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ABSTRACT   1 
Protease activated receptor 2 (PAR2) is an unusual G-protein coupled receptor 2 
(GPCR) involved in inflammation and metabolism. It is activated through cleavage of its 3 
N-terminus by proteases. The new N-terminus functions as a tethered ligand that folds 4 
back and intramolecularly activates PAR2, initiating multiple downstream signaling 5 
pathways. The only compounds reported to date to inhibit PAR2 activation are of 6 
moderate potency. Three structural models for PAR2 have been constructed based on 7 
sequence homology with known crystal structures for bovine rhodopsin, human ORL-1 8 
(also called nociceptin/orphanin FQ receptor) and human PAR1. The three PAR2 model 9 
structures were compared and used to predict potential interactions with ligands. Virtual 10 
screening for ligands using the Chembridge database and either ORL-1 or PAR1 derived 11 
PAR2 models led to identification of eight new small molecule PAR2 antagonists (IC50 12 
10 – 100 μM). Notably, the most potent compound 1 (IC50 11 μM) was derived from the 13 
less homologous template protein, human ORL-1. The results suggest that virtual 14 
screening against multiple homology models of the same GPCR can produce structurally 15 
diverse antagonists and that this may be desirable even when some models have less 16 
sequence homology with the target protein. 17 
 18 
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INTRODUCTION  1 
G protein-coupled receptors (GPCRs) have been by far the most successful targets 2 
for the development of pharmaceuticals, with 30% of current pharmaceuticals directed at 3 
a GPCR on the surface of cells1-3. However, finding lead compounds for this target class 4 
has had to be achieved through painstakingly iterative structure-activity evaluations of 5 
small molecules, usually derived from endogenous activators, hormone fragments or 6 
high-throughput screening of natural products and synthetic libraries1,2. An alternative 7 
approach to ligand discovery is automated in silico docking of virtual chemical libraries 8 
into computer-derived structural homology models of GPCRs created by aligning the 9 
sequence of a target GPCR with that of a homologous GPCR where there is a known 10 
crystal structure4-6.  11 
Protease activated receptor 2 (PAR2) is an unusual GPCR where there is no 12 
known endogenous ligand. Instead, this GPCR is activated by proteases. Its extracellular 13 
N-terminus is cleaved predominately by trypsin-like serine proteases to reveal a 14 
‘neoepitope’ called the tethered ligand (TL), (e.g. SLIGKV, human; SLIGRL, murine), 15 
which binds intramolecularly and activates PAR2 at an unknown site7,8. PAR2 is 16 
expressed in many mammalian tissue types including in the immune, cardiovascular, 17 
respiratory, nervous and musculoskeletal systems. Studies have shown that PAR2 18 
activation is associated with metabolism, inflammation, pain, proliferation, metastasis, 19 
and angiogenesis, in many cancers including pancreatic, colon, breast, prostate and 20 
stomach9-11. Thus, compounds targeting PAR2 may be suitable for modulating a wide 21 
range of diseases.  22 
 4 
To date, the development of PAR2 modulators has proceeded predominantly via 1 
structural modifications of synthetic peptides that correspond to the protease-cleaved new 2 
N-terminal PAR2 sequence leading to a variety of hexapeptide agonists that are called 3 
activating peptides (PAR2-APs)12,13. Although much less potent than trypsin, these 4 
PAR2-APs were found to be selective agonists for PAR2 over PAR114. Later, PAR2-APs 5 
were further refined by replacing the N-terminal serine with a furoyl group15, and the 6 
resulting 2f-LIGRLO-NH2 is a sub-micromolar PAR2 agonist (EC50 ~200 nM, Ca2+ HT29 7 
cells)16. Our group has reported low molecular weight, serum stable, non-peptidic 8 
agonists (e.g. GB110, EC50 ~200 nM, Ca2+, HT29 cells)17, and antagonists (e.g. GB88, 9 
IC50 1-10 μM, Ca2+)16 in a variety of human cell lines. GB88 has shown benefits in vitro 10 
and in vivo in rodent models of disease18-20 and has encouraged subsequent development 11 
of PAR2-directed small molecules.  12 
Many drug discovery programs begin with structure-based virtual screening, 13 
which is a process to identify and prioritize molecular binders of a target protein in silico, 14 
followed by in vitro and in vivo experimental validation. However, the discovery of new 15 
GPCR modulators using this method has usually proven to be difficult as structural 16 
characterization for membrane-spanning GPCRs has, until recently, been less successful 17 
than for other proteins and enzymes. Creating a homology model of a GPCR, based on a 18 
related GPCR for which there is a crystal structure, can be helpful in identifying putative 19 
ligands. A decade ago, GPCR modeling was restricted by the availability of a single 20 
template (bovine rhodopsin) for structure prediction. However, the number of high-21 
resolution GPCR crystal structures has steadily increased over the last eight years21.  22 
 5 
Here, we compare three homology structural models for human PAR2, 1 
successively constructed over seven years as newer and more homologous high-2 
resolution structures (bovine rhodopsin, ORL-1, PAR1) became available as modeling 3 
templates. The model built from different templates was performed by different people 4 
and at different times using differing software approaches in our group. The quality of 5 
each of the models was assessed using a range of protein structure assessment tools. The 6 
models were also assessed by putative binding site analysis for their potential to be useful 7 
for docking known PAR2 ligands. The two most reasonable models were then further 8 
compared for their efficiency in enriching known PAR2 antagonists (from our lab) using 9 
a small set of drug-like decoys from Schrödinger (www.schrödinger.com). These two 10 
models were used to screen commercially available Chembridge compounds in silico. 11 
Hierarchical virtual screening was performed involving database filtering, scoring and 12 
ranking compounds for predicted binding affinity for PAR2, visual inspection and 13 
compound clustering analysis. This paper describes 71 compounds that were purchased 14 
and assessed for PAR2 agonist and antagonist activity in a calcium mobilization assay. 15 
This work led to the identification of eight non-peptidic PAR2 antagonists with minimal 16 
or no agonist activity, making this the first reported virtual screening study for this target 17 
and it has confirmed the potential of homology models for identifying PAR2 ligands and 18 
for studying protein-ligand structures. 19 
 20 
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METHODS  1 
Focused Sequence Identity and Similarity Comparison 2 
Sequence identity and similarity of the 7-TM region and ligand accessible region 3 
between PAR2 and the three templates selected were calculated (Table 1) using 4 
GPCRDB tools (http://tools.gpcr.org/). A multiple sequence alignment comparing PAR2 5 
sequence and the three template sequences is shown in Figure S1. 6 
 7 
Homology Modeling based on Bovine Rhodopsin  8 
The human PAR2 protein sequence was obtained from Swiss-Prot website 9 
(Accession number – P55085) and aligned with the sequence of the bovine rhodopsin 10 
crystal structure (1U19, TM sequence identity = 21%, resolution = 2.20 Å)22  using the 11 
PAM-250 matrix, which aligns the sequence based on conservation of charged, bulky 12 
aliphatic or aromatic residues. Alignment was refined manually by taking the 13 
transmembrane (TM) regions and structurally conserved regions into consideration, the 14 
study of Bissantz et al being a reference point for this work23. The seven transmembrane 15 
regions were identified based on the conservation of residues in each putative 16 
transmembrane region. This alignment was used to develop the coordinates of the TM 17 
regions using the Modeller program within InsightII Modelling Environment, Release 18 
2000;  (Accelrys Inc., San Diego, California, USA, http://www.accelrys.com) using 19 
default parameters; a cysteine disulfide bond constraint between C148 on TM3 and C226 20 
on extracellular loop 2 was included. The loop regions were also developed by Modeller 21 
using the rhodopsin template. The final model was further refined to remove steric 22 
clashes within the molecule by a minor modification of the minimisation (the Newton 23 
 7 
minimization algorithm was not performed because of the large number of atoms in the 1 
protein). Additionally, in this minimization protocol the backbone atoms of the TM 2 
regions were kept tethered to maintain the helical conformation of the TM regions. This 3 
final minimized conformation was used for model validation. 4 
 5 
Homology Modeling based on ORL-1 and PAR1  6 
The human PAR2 protein sequence was obtained from Swiss-Prot (Accession 7 
number – P55085) and aligned using sALign to the sequence of the crystal structure of 8 
the nociceptin/orphanin FQ/ORL-1 receptor (4EA3, TM sequence identity = 29%, 9 
resolution = 3.01 Å)24 and human PAR1 (3VW7, TM sequence identity = 44%, resolution 10 
2.2 Å)25, respectively. This alignment was then manually inspected and adjusted in 11 
Jalview26.  Model construction was performed using Modeller 9v1027, 20 all atom 12 
homology models were built for the ORL-1 model, whereas 40 were constructed for the 13 
PAR1 based model. The co-crystallized ligand was removed from the ORL-1 crystal 14 
structure prior to model construction, however it was retained in the PAR1 crystal 15 
structure to prevent side chains from occupying the putative binding site during model 16 
construction. The model with the lowest discrete optimization protein energy (DOPE) 17 
score was selected for further refinement. The whole ECL2 in the ORL-1 based model 18 
was further refined using the loop refinement option (default setting) in Prime (version 19 
3.1, Schrödinger, LLC, New York, NY, 2012) and the final model that incorporated the 20 
optimized ECL2 was minimized in Prime using the truncated-Newton energy 21 
minimization (OPLS_2005 force field with restrained helical backbone). Two regions 22 
with little homology in ECL2 (V211-I218 and L230-Q233) were further refined in the 23 
 8 
PAR1 based model using Modeller. Induced-fit docking28,29 within the Schrödinger Suite 1 
v9.3.518 (Schrödinger, LLC, New York, NY, 2012) was performed on the PAR1-derived 2 
PAR2 model using the most potent non-peptidic PAR2 ligand currently available, 3 
GB110.  The final models were refined using the protein preparation wizard30 in 4 
Schrödinger to optimize hydrogen bond networks and for a restrained energy 5 
minimization (OPLS_2005 force field and heavy atom movement <0.5 Å). 6 
 7 
Quality Assessment and Validation of Homology Models  8 
The quality of the homology models was assessed for different physical and 9 
chemical parameters. The “structure assessment” module available at Swiss-Model portal 10 
(http://swissmodel.expasy.org/) was used for local model quality estimation (QMean 11 
score31), global model quality estimation (DFIRE energy32) and stereochemistry check 12 
(Procheck). ERRAT33 program was also used for model reliability prediction.  13 
 14 
Molecular Docking 15 
Molecular structures of PAR2 agonists, 2f-LIGRLO-NH2 and GB110, were drawn 16 
in ChemDraw Std 13.0, exported as 2D structures and converted to 3D coordinates using 17 
LigPrep in Schrödinger Suite software (version 9.4). LigPrep generated 3D structures of 18 
the ligands with that was minimized using the OPLS2005 force field and protonation 19 
state corrected to pH 7.4 using Epik. The newly generated 3D structures were saved as 20 
mol2 files for docking. GOLD v5.134 was used to dock ligands into the putative binding 21 
site. In the ORL-1 based model, the active site was centered with a 15 Å radius around 22 
residue F1553.32, this active site was visually inspected to ensure residues from binding 23 
 9 
cavity analysis and hotspot literature survey were included. Fifty GA runs were 1 
performed with flexible residue side chains incorporated for F155, Y156, F243, N304, 2 
L307, and Y326. In the PAR1 based model, none of the side chains were required to be 3 
flexible to obtain a reasonable pose. 4 
 5 
Small Scale Enrichment Study 6 
 A small number of PAR2 antagonists (8 in total) developed in our lab were added 7 
to the Schrodinger “drug like decoy compound library” and docked into ORL-1 and 8 
PAR1 derived PAR2 models respectively. The ability of the model to discriminate 9 
between the actives and decoys was measured by a comparison of their enrichment 10 
factors determined at the top 2%, 5%, and 10% of docked poses. This enrichment factor 11 
(EF) is an indicator of the potential performance of a model against which a compound 12 
library is screened. EF is defined as the ratio of the percentage of active compounds in 13 
the subset chosen to the percentage of active compounds in the whole database used for 14 
screening35. In our study, we define the enrichment factor as: 15 
 Enrichment Factor (EF) = 
!"#$%&'(%*+,-./01(%*+,-./0 ∙ 1343+.!"#$%&'343+.	 16 
Where Actives=%>?@ABCD	is the number of actives found at x% of the database screened, 17 𝑁=%>?@ABCD is the number of compounds screened at x% of the database, ActivesFGF?B is 18 
the number of active compounds in the entire database, and 𝑁FGF?B is the number of 19 
compounds in the entire database. 20 
 21 
Virtual screening 22 
 10 
Figure 1 summarizes the schematic workflow for the virtual screening. Briefly, 1 
the Chembridge database of purchasable compounds was prepared for virtual screening 2 
using the program FILTER36-37 and OMEGA38 (OpenEye Scientific Software Inc, Santa 3 
Fe, NM) to provide two ligand databases. The first consisted of a library of ~310,000 4 
small lead-like molecules (MW <350) and the second was a library containing ~330,000 5 
drug-like molecules of larger molecular weight (MW 356-600).  Each database was 6 
separately screened against each model in two rounds, using GOLD v5.1. The initial 7 
screen was performed with a single Genetic Algorithm (GA) run at 10 % efficiency 8 
(standard virtual screen setting). GoldScore was applied to select the best scoring 8000 9 
compounds. The second round consisted of a single GA and 30 % efficiency, using 10 
GoldScore to select the best scoring 200 compounds. From this list, compounds were 11 
visually inspected for predicted interactions with the receptor by taking into account 12 
putative key residues during binding pocket analysis and “hotspot” residue searches. 13 
Final compound selections were filtered against the pan assay interference compounds 14 
sub-structural filter39 as implemented in Canvas (version 1.6, Schrödinger, LLC, New 15 
York, NY, 2013). 16 
 17 
Purchased Compounds 18 
 All compounds were purchased from Chembridge without further purification. 19 
According to the vendor, all compounds provided were analysed by LC-MS and/or NMR 20 
spectroscopy to confirm sample identity and the purity was ≥ 95%. Stock solutions were 21 
prepared by dissolving compounds in DMSO-d6 and were characterized in house as well 22 
 11 
by 1H NMR spectroscopy. The exact concentration of each compound was determined by 1 
the quantitative NMR integration ‘PULCON’ experiment.40 2 
 3 
Intracellular calcium mobilization assay 4 
Cell culture was performed according to previously described protocol20. Briefly, 5 
HT29 colorectal adenocarcinoma cells were cultured in DMEM supplemented with 10 % 6 
fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 U/mL) at 37°C with 5 7 
% CO2. Cell dissociation solution was used to dissociate cells from the surface of culture 8 
flasks. Cells were grown to 80 % confluence. The day before experiments, cells were 9 
seeded in 96 well black walled, clear bottom plates at 5 x 104 cells per well. On the day of 10 
the experiment, supernatant was removed and the cells were incubated in dye loading 11 
buffer (4 μM Fluo-3, 0.04% Pluronic acid and 1% fetal bovine serum in HBSS) for 1 h at 12 
37°C. Cells were then washed twice with HBSS. For agonist assays, cells were then left 13 
in 50 μL of HBSS, transferred to a FLIPR Tetra (Molecular Device, Sunnyvale CA) for 14 
addition of compound. Fluorescence was measured in real time from the bottom of the 15 
plate using excitation λ = 480 nm and emission detection at 520 nm. Antagonist assays 16 
involved pre-incubating the cells with the test compounds for 30 minutes before addition 17 
of the agonist (1 μM 2f-LIGRLO-NH2). Agonist activity was normalized against 100% 18 
Ca2+ response for 100 μM 2f-LIGRLO-NH2, while antagonist activity was normalized 19 
against 1 μM 2f-LIGRLO-NH2. The IC50 for each antagonist was determined by fitting 20 
data to a non-linear regression curve in GraphPad Prism 6.0, GraphPad Software, San 21 
Diego California USA, www.graphpad.com. 22 
 23 
 12 
RESULTS AND DISCUSSION  1 
Construction of PAR2 Homology Models 2 
 GPCRs vary enormously in sequence, structure, the sizes of extracellular and 3 
intracellular loops, and the lengths of the extracellular N- and intracellular C-termini. 4 
However, the conservation of a canonical transmembrane 7-helix bundle in all rhodopsin 5 
family members facilitates effective modeling comparisons for the transmembrane 6 
domains of GPCRs. Our first PAR2 homology model was created based on the crystal 7 
structure of bovine rhodopsin, being the only GPCR crystal structure available at the 8 
time. It has a very low TM sequence identity with PAR2, so we waited for crystal 9 
structures to be developed before constructing more reliable PAR2 models. More recently 10 
crystal structures for other class A GPCRs have been reported and were more 11 
homologous templates, so we constructed new PAR2 structural homology models based 12 
ORL-1 (PDB ID: 4EA3) and subsequently released PAR1 (PDB ID: 3VW7). These two 13 
receptors also engage native peptide ligands and so they were expected to provide better 14 
PAR2 modeling templates than other class A GPCRs.  15 
 16 
Assessment of 3 Homology Models for PAR2 17 
The structural homology models derived from each of the three template-derived 18 
constructions of PAR2 were submitted to SwissModel portal and ERRAT for evaluation 19 
of model quality and stereochemical properties.  The assessment of model quality related 20 
parameters such as Qmean6 score, DFIRE energy, Ramachandran statistics and ERRAT 21 
score, which are summarized in Table 2. For comparison, the original crystal structures of 22 
the three templates were also submitted for SwissProt evaluation. Qmean6 score is a 23 
 13 
linear combination of six structural descriptors and a higher Qmean6 (range between 0 1 
and 1) reflects strong reliability of the model31. DFIRE is an all-atom statistical potential 2 
term used to assess non-bonded atomic interactions in the protein model32. All models 3 
produced comparable scores for these two components, relative to the templates from 4 
which they were constructed. These results suggested that the constructed homology 5 
models were both stereochemically and energetically reliable structures.  6 
A Ramachandran plot for each PAR2 model is shown in Figure S2. All residues 7 
in the rhodopsin based homology model were located in the favored and allowed φ-ψ 8 
regions, whereas 99.2% and 99.6% of the residues from the ORL-1 and PAR1 based 9 
homology models were located in the same regions. For ORL-1 and PAR1 based models, 10 
a closer check of residues located in the non-favorable regions revealed that these 11 
residues belong to the loop regions. For example, A220 and E232ECL2 in the ORL-1 based 12 
model are residues in extracellular loop 2 (ECL2), or M181 in the PAR1 based model is 13 
in intracellular loop 2 (ICL2). It was noticed that ECL2 of PAR2 has 23 residues whereas 14 
the ORL-1 structure has 20. Hence, the inclusion of three extra residues could produce 15 
some alteration in the ECL2 region as evidenced by the disallowed backbone angles of 16 
these two residues.  Overall, the Ramachandran analysis indicated that the backbone 17 
stereochemical properties for all three PAR2 models were close to the protein crystal 18 
structures. In addition, an ERRAT score was also calculated for each model. ERRAT is a 19 
statistical method used to distinguish errors in model building, leading to more 20 
randomized distributions of different atom types in protein residues33. The higher ERRAT 21 
scores of PAR1 (85.7%) and ORL-1 (83.6%) based models, as compared to the rhodopsin 22 
based model (81.5%), suggested that they were closer to crystal structures solved at a 23 
 14 
moderate resolution between 2.5-3.0 Å with an average overall ERRAT quality factor of 1 
91%.  2 
 3 
Overall Model Comparison 4 
Figures S3-S5 show cartoon representations of all three homology models. After 5 
careful PAR2 sequence alignment to its template structure, all models formed intact 6 
canonical 7-helical bundles within the transmembrane (TM) region. The TM backbone 7 
R.M.S.D between each PAR2 homology model and their template was 0.37 Å (rhodopsin 8 
based), 0.27 Å (ORL-1 based) and 0.09 Å (PAR1 based) respectively. The most 9 
prominent difference in the three models was the positioning of ECL2 on top of the 10 
receptor. This is not surprising as the three templates used for model construction 11 
featured different ECL2 residues in both length and identity. Loop prediction and 12 
construction represents a major challenge for the modeling of GPCRs, particularly ECL2 13 
due to its large size and high flexibility. Furthermore ECL2 is commonly involved in 14 
ligand binding and stabilization of the exterior of TM bundle.  15 
Studies on both human PAR1 and PAR2 have implicated residues on ECL2 as 16 
being important for receptor activation41. In the rhodopsin (PDB ID: 1U19) based 17 
homology model (Figure S3), ECL2 adopted a random loop that was deeply buried into 18 
the surface of the TM bundle and it fully blocked entry to the ligand-binding TM cleft in 19 
PAR2. In the ORL-1 (PDB ID: 4EA3) based model (Figure S4), ECL2 adopted a solvent-20 
exposed β-hairpin, situated on top of TM3, TM4 and TM5, allowing ligand access to the 21 
binding cavity. In stark contrast to the location of ECL2 observed in the ORL-1 based 22 
homology model, ECL2 in the PAR1 (PDB ID: 3VW7) based model (Figure S5) almost 23 
 15 
entirely covered the ligand-binding site. Considering the sequence homology in ECL2 1 
residues present between PAR2 and the three templates, PAR1 (65% sequence identity) 2 
offers an apparent advantage over ORL-1 (15% sequence identity) and rhodopsin (19 % 3 
sequence identity). Published crystal structures of class A GPCRs have shown a variety 4 
of defined secondary structures present within ECL242. The human PAR1 ECL2 5 
displayed a β-hairpin and the residues involved in this secondary structure are completely 6 
conserved between PAR1 and PAR2, suggesting that this β-hairpin may also be present 7 
in the PAR2 structure. However, the secondary structure of ECL2 in the human PAR1 8 
crystal structure could have been induced by the bound antagonist (vorapaxar), permitting 9 
interactions between side chains of ECL2 and bound ligand. The actual positioning of 10 
this loop in PAR2 is still unknown.  Therefore, the ORL-1 based model with a different 11 
ECL2 position provides an alternative clue to the potential location of ECL2 in PAR2. 12 
 13 
Relative Position of Key Aromatic TM Residues 14 
Mutagenesis studies from our lab have revealed the importance for some TM 15 
aromatic residues for ligand binding to PAR243. Among them are Y821.39, Y1563.33, 16 
Y3267.35 and Y3116.59 and their relative locations in each homology model were 17 
compared. For a clearer view of these residues in the TM region, the top view of the 18 
receptor model is shown for all the models. Furthermore, the superimposed models are 19 
shown in Figure 2. Substantial differences in the position and orientation were observed 20 
for Y3116.59 and Y3267.35. The sidechain of Y3267.35 still projects into the centre of the 21 
helix bundle, however it is located one helical turn above in the rhodopsin-based model 22 
compared to the other two models. In rhodopsin, P7.35 is at the top of TM7. This was in 23 
 16 
agreement with the finding that ORL-1 and rhodopsin contain several extra residues at 1 
the border of ICL3 and TM6, while also containing less amino acids at the border of TM6 2 
and ECL3. Such a difference may lead to dramatic variations in the overall length and 3 
folding fidelity of TM6 and TM7, which may explain the differences observed in 4 
template dependent models. In contrast, Y821.39 and Y1563.33, were modeled in a more 5 
similar position with little variation in orientation. 6 
A particular feature of the PAR1 based homology model of PAR2 is the 7 
proximity of the side chains of Y1563.33 and Y3267.35. This close association is stabilized 8 
through a side chain hydrogen bond between the two residues and forms the base of a 9 
binding pocket in PAR1 based model. Of note, these two residues also provide a 10 
hydrophobic base on which the lipophilic vorapaxar sits in the PAR1 structure. In the 11 
PAR2 structures modeled from rhodopsin and ORL-1, these two tyrosine residues were 12 
far apart (Tyr side chain hydroxyl group distOH-OH being 8.6 Å and 8.1 Å, respectively) 13 
from each other.  14 
 15 
Putative Ligand Binding Site Comparison 16 
Owing to the different location of ECL2 in the three models, the accessible 17 
binding pocket of the models varied accordingly. CASTp44 calculation showed that the 18 
rhodopsin-based model had a restricted binding cavity for ligands. The largest cavity 19 
volume for this model was only 275 Å3, posing a potential challenge for further ligand 20 
docking. The binding surface in this model was optimal for docking only when either 21 
ECL2 was removed or when applying flexible residues (e.g. D228ECL2) during docking, as 22 
most of the docked poses scored negatively, indicating steric clashes between receptor 23 
 17 
residues and the ligand. This was not ideal for later large-scale virtual screening which 1 
was performed with a rigid receptor in order to minimize time and cost. With this caveat, 2 
the rhodopsin based homology model will also be reported for our recent study of ligand 3 
docking and mutagenesis used in conjunction to characterize PAR2 residues that 4 
influence activation by the synthetic agonists 2f-LIGRLO-NH2 and GB11038. The largest 5 
pocket in the ORL-1 based model had a much larger volume of 2764 Å3 (Figure 3). In the 6 
PAR1 based model Y1563.33 and Y3267.35 act as gate-keepers, dividing the binding pocket 7 
into two halves. The left cavity had a relatively larger volume of 1075 Å3, compared to 8 
the smaller 600 Å3 right cavity. A crystal structure based comparison of common (hot 9 
spot) TM residues involved in ligand interaction from several other class A GPCRs (e.g. 10 
Turkey β1 adrenergic receptor bound to cyanopindolol (PDB: 2VT445); Dopamine D3 11 
receptor bound to eticlopride (PDB: 3PBL46); Chemokine CXCR4 receptor bound to 12 
1T1t (PDB: 3ODU47); Chemokine CCR5 receptor bound to maraviroc (PDB: 4MBS48)), 13 
together with information on ligand accessible site available at GPCRDB, led us to 14 
identify and match several analogous residues in PAR2 with those in the three template 15 
proteins used here (Table 3). As PAR1 and PAR2 share the highest TM sequence 16 
homology (44 %), there was also high homology among the class A hotspot residues. The 17 
four key aromatic TM residues mentioned above were included in the cavity shown in 18 
Figure 3. Considering the positioning of ECL2, the analysis of key aromatic TM residues 19 
and the binding site comparison among the three models, it was decided that further more 20 
detailed characterization should focus instead on the ORL-1 and PAR1 based homology 21 
models of PAR2. 22 
 23 
 18 
Molecular Docking Into PAR2 1 
In order to explore the potential applicability of the ORL-1 and PAR1 derived 2 
models of PAR2 for in silico screening, a peptidic PAR2 agonist 2f-LIGRLO-NH2 (HT29 3 
cells EC50 210 nM) and a modified non-peptidic PAR2 agonist GB110 (HT29 cells EC50 4 
280 nM) were docked into each PAR2 model structure. Interactions involving key 5 
residues shown to be important for PAR2 activation from our recent mutagenesis study43 6 
are compared here. 7 
Docking of 2f-LIGRLO-NH2 into the ORL-1 based model of PAR2 (Figure 4) 8 
suggested polar contacts with three residues (Y1563.33, Y3116.59, D228ECL2) known to be 9 
important for receptor activation. A potential cation-π interaction between R5 and Y242 10 
was also predicted by docking. Y3116.59 and D228ECL2 were captured as plausible 11 
interacting residues from ligand docking into the PAR1-derived PAR2 model. Although 12 
polar contacts between 2f-LIGRLO-NH2 and D228ECL2 and Y3116.59 were sampled in both 13 
models, this ligand was positioned in opposite orientations in these two models. In the 14 
ORL-1 based model, the furoyl group oriented towards a pocket between TM2 and TM7, 15 
while in the PAR1 based model the furoyl group was docked between TM5 and TM6.   16 
The proposed binding mode of GB110 in the ORL-1 based model (Figure 5) 17 
positions equivalent elements of GB110 in a similar pose as 2f-LIGRLO-NH2. Polar 18 
contacts with Y1563.33 and D228ECL2 are still present, in addition to polar contacts to 19 
Y821.39 and Y3267.35. In the human PAR1 based model for PAR2, GB110 is also proposed 20 
to adopt a similar pose to 2f-LIGRLO-NH2. Similar polar contacts with Y3116.59 and 21 
D228ECL2, also H227ECL2 and E232ECL2, were found. Similarly to the poses of 2f-LIGRLO-22 
NH2, opposite orientations of GB110 were found in the two models.  23 
 19 
Considering the differences observed in the putative binding site, it was expected 1 
that one of the models would position the PAR2 agonists within close proximity to more 2 
amino acids known to be important for receptor activation. Docking results predicted 3 
residues that have been confirmed by PAR2 mutagenesis studies as being important for 4 
PAR2 activity43 and this encouraged our use of model-based virtual screening for 5 
discovery of novel PAR2 modulators. 6 
Small Scale Enrichment Study 7 
Prior to virtual screening of a commercial database of potential ligands for PAR2, 8 
a preliminary small-scale enrichment calculation was conducted on the ORL-1 and PAR1 9 
based models. This can provide information indicating the potential performance of the 10 
models in returning a higher hit rate in virtual screens. The small- scale virtual screening 11 
library consisted of 8 PAR2 antagonists and 1000 Schrödinger decoy compounds. 12 
Surprisingly, both models gave similar enrichment factors of EF2% (0.0), EF5% (2.5) 13 
and EF10% (1.25), indicating similar performance of the two models in predicting hits 14 
from this training set of ligands. However, the EF study is very dependent on the 15 
structural diversity and activities of the compounds used to enrich the data set, the lack of 16 
alternative PAR2 antagonists placing a heavy reliance on only in-house synthetic ligands. 17 
Consequently, the EF calculation here may not be sufficient to truly reflect the quality of 18 
the models. In this context, a prospective virtual assessment of a large chemical library 19 
followed by experimental validation of putative ligands in biochemical assays is needed 20 
to validate PAR2 homology models reported herein. 21 
 22 
Virtual Library Screening  23 
 20 
To utilize the two PAR2 homology models to discover new PAR2 modulators, we 1 
performed large-scale virtual library screening of the Chembridge database containing 2 
~700,000 compounds.  3 
The virtual screening workflow was identical for the ORL-1 and PAR1 based 4 
models. 71 compounds (Figures S6-S9) were identified as hits from virtual screening 5 
using both homology models. These compounds were assayed for PAR2 agonist and 6 
antagonist activity in HT29 colon cancer cells, a highly expressing PAR2 cell line. From 7 
initial assays, compounds inhibiting PAR2 activation (>50%) at 100 μM were further 8 
studied in a concentration-dependent manner for inhibition of PAR2-mediated 9 
intracellular Ca2+ release induced by 1 μM 2f-LIGRLO-NH2.  Compounds 1-4 (IC50 11-10 
44 μM) were identified as PAR2 antagonists from the ORL-1 based model and four 11 
different compounds 5-8 (IC50 30-94 μM) were obtained from the PAR1 based model 12 
(Table 4). Figure 6A and 6B illustrate the pharmacological profiles of just compounds 1 13 
and 5 (six other antagonists are shown in Figure S10) in both agonist and antagonist 14 
assays for PAR2 Ca2+ mobilization. Encouragingly, except for compound 5 which 15 
exhibited about 25% activation of Ca2+ release at the highest concentration tested (100 16 
µM), all the compounds proved to be pure antagonists of 2f-LIGRLO-NH2 without 17 
causing significant PAR2 activation when examined alone with no added agonist (HT29 18 
cells). 19 
These results may reflect a degree of transferability between models of the 20 
inactive form of the template crystal structures, supporting functional fidelity of docking 21 
ligands to the conformation of the GPCR, which is in good agreement with previous 22 
virtual screens conducted with other GPCR homology models49. A caveat of GPCR 23 
 21 
homology modeling lies in the inactive conformational state induced by an antagonist, 1 
which is often necessary for conformational stabilization and therefore favors 2 
crystallization conditions. This effect has been consistently shown to influence the 3 
activity of hits derived from virtual screening GPCR homology models based on these 4 
inactive structures. Meanwhile, the higher proportion of active molecules discovered 5 
from the library of compounds with MW 350-600, for both models, is likely due to the 6 
nature of the binding site of PAR2, which can accommodate peptidic ligands.  7 
To understand possible interactions between the most potent antagonists derived 8 
from the two parallel virtual screens of PAR2, docked poses of 1 and 5 in the ORL-1 and 9 
PAR1 based models respectively were analysed (Figure 7). Consistent with the 10 
observation of the docked pose for 2f-LIGRLO-NH2 and GB110, the overall binding 11 
region and orientation occupied by the two antagonists adopted a similar pattern. In the 12 
docked complex of compound 1 and the ORL-1 based model, the phenyl ring was docked 13 
between TM2 and TM3, forming interactions with W127, pyrazolol-pyrimindine formed 14 
a parallel-displaced pi stacking arrangement with F155, the piperidine ring was predicted 15 
to binding in between Y1563.33 and Y3267.35. As this group is prone to protonation, we 16 
surmise that a potential hydrogen bond might be formed with a receptor residue although 17 
this was not observed from docking simulation. The pyrimidine ring intercalated between 18 
H3106.58 and Y3116.59, contributing to aromatic interactions that can further stabilize 19 
ligand binding. One of the nitrogen atoms was predicted to form a hydrogen bond 20 
interaction with the amine NH on K315, a residue within ECL3. In contrast, compound 5 21 
from the PAR1 based model was docked above the base formed by the two tyrosines, 22 
Y1563.33 and Y3267.35. Intriguingly, this compound also contained a piperidine ring in the 23 
 22 
central region of the molecule, and it was also positioned in proximity to Y1563.33, 1 
Y3116.59 and Y3267.35. The thiophene in compound 5 was predicted to bind between TM3 2 
and TM5, surrounded by Y1563.33 and F251. The quinazoline bicyclic ring is situated 3 
perpendicular to Y3267.35, forming a T-shaped edge–to-face π-aryl interactions with this 4 
residue. The terminal methylsulfonyl group is oriented towards ECL2 residues H227ECL2 5 
and D228ECL2.  The putative binding of these two hits was supported by a ligand binding 6 
assay (Figure S11). Hits from the ORL-1 based model all showed weak binding affinity, 7 
while two hits from the PAR1 based model competed for binding against 2f-8 
LIGRLO(dpta)-NH2. Compound 5 exhibited the highest competitive binding affinity 9 
(70%) towards CHO-hPAR2 at 100 μM, whereas compound 1 showed only 35% 10 
competitive binding. Compounds 6 and 8 did not compete at the highest concentration 11 
tested. Although this is in agreement with their low potency in the Ca2+ assay, it must be 12 
said that the competition assay is limited in only identifying binding to the same site as 13 
the labeled ligand. Further, we surmise that the binding pocket in the PAR2 homology 14 
model derived from ORL-1 and PAR1 may represent different allosteric binding site of 15 
PAR2 antagonists identified, which rendered all hits weak antagonists. So far little is 16 
known about the orthosteric binding site of the PAR2 tethered ligand and it is beyond our 17 
scope here to further investigate this. However, results presented here do suggest that the 18 
dynamic and flexible nature of the PAR2 structure in current models offers alternative 19 
and not mutually exclusive templates for discovery of structurally different ligands.  20 
PAR2 antagonists with novel scaffolds and a degree of chemical diversity were 21 
discovered from these virtual screening approaches with a surprisingly high hit rate of 22 
10.3% (ORL-1 based model) and 12.5% (PAR1 based model). The majority of PAR2 23 
 23 
ligands reported in the literature are peptidic, developed from the canonical tethered 1 
ligand19. While discovery of potent small molecule antagonists for this receptor has been 2 
problematic, we report here the first success in homology modeling-based virtual 3 
screening for PAR2. Both models selected for virtual screening returned hits with 4 
moderate potency. This approach is clearly useful in providing new structural templates 5 
for ligand-based optimization to derive more potent analogues. The most potent 6 
compound 1 (IC50 11 μM) has MW = 386 Da, cLogP = 2.55, 2 hydrogen bond donors, 7 7 
hydrogen bond acceptors, tPSA 72 Å2, and 5 rotatable bonds (Table S1), indicated the 8 
kinds of properties sought for virtual hits. Encouragingly, the results suggest that the 9 
models have a different degree of accuracy in predicting the putative conformation in the 10 
binding site of PAR2.  11 
The homology structural model for PAR2 can very likely be further refined to 12 
improve the screening rate for PAR2 modulators. Current virtual screens are conducted 13 
against a rigid receptor, because flexible virtual screening is more computationally 14 
demanding. Interestingly, at the time of preparing this manuscript, Rataj et al reported the 15 
low impact of choosing the most closely related phylogenetic template based on 16 
homology model efficiency in virtual screening for four serotonin receptors50. We also 17 
found from our virtual screening, that the hit rate was not solely dependent on a high 18 
overall sequence identity between PAR2 and its template crystal structure, or even the 19 
sequence homology between residues in the ligand-binding pocket. Indeed the more 20 
potent hits in this study were obtained using the less homologous template (human ORL-21 
1). These results contrast to the GPCR Dock 2010 assessment, which concluded that only 22 
closely related proteins are suitable for GPCR homology modeling51. That assessment 23 
 24 
from GPCR Dock focused on predicting the binding modes of ligands in static crystal 1 
structures. To some extent, such an assessment is restricted by the central premise that the 2 
docked complex in the homology model would be expected to be close to the crystal 3 
structure. However, for the virtual screening herein, we were interested in identifying 4 
structurally diverse ligands.  5 
Thus, we recommend that future studies investigating in silico screening of 6 
GPCRs should utilize more than one template in parallel, in order to access wider 7 
conformational sampling of the dynamic states of a GPCR and hence potentially sample 8 
more structural diversity in ligand hits, rather than relying on a static solid state crystal 9 
structure should it be available.  10 
 11 
CONCLUSIONS  12 
Three structurally reliable and energetically reasonable homology models of the 13 
structure of PAR2 are reported here. Detailed comparisons of TM residues, ECL2 and the 14 
binding cavities led us to prioritize the ORL-1 and PAR1 based models for further 15 
molecular docking and virtual screening of putative ligands. Eight novel structurally 16 
diverse PAR2 antagonists (with negligible or no agonist activity) were identified, with 17 
IC50 values ranging from 10-100 μM against 1µM 2f-LIGRLO-NH2 in HT29 colon 18 
cancer cells. Despite a lower TM sequence identity and similarity to PAR2, the ORL-1 19 
based model returned an almost equal hit rate to that obtained from the more closely 20 
related and more sequence-homologous template, PAR1. Thus, the common practice of 21 
using the template structure with the highest sequence identity for GPCR modeling may 22 
not necessarily be ideal and templates of lower homology might produce equipotent hits 23 
 25 
in virtual screening campaigns. It may be valuable to use a set of homology models 1 
derived from templates with different sequence similarity and binding pocket variations 2 
in the TM region, and thus different conformations to that stabilized in the solid state as 3 
elucidated by a crystal structure, in order to capture structurally diverse sets of potential 4 
ligands through virtual screening discovery programs. Subsequent hit-to-lead campaigns 5 
can benefit greatly from structurally diverse hits as alternative starting points for 6 
medicinal chemistry optimization programs.  7 
 8 
Figures and Tables 9 
 10 
 11 
Figure 1. Schematic workflow for virtual screening of putative antagonists against PAR2 12 
homology models. 13 
 14 
 26 
 1 
 2 
 3 
Figure 2. Superimposed homology models of PAR2 derived from bovine rhodopsin, 4 
human ORL-1 and human PAR1, with ECL2 removed to clarify comparison of TM 5 
residues as highlighted. This figure was generated using PyMOL52. 6 
 7 
 8 
 9 
 10 
 11 
 27 
 1 
Figure 3. Surface representation of ORL-1 and PAR1 derived homology models of 2 
PAR2 with highlighted putative ligand-binding cavity: (A) ORL-1 based model; (B) 3 
PAR1 based model. ECL2 in each model is colored gray. Residues involved in putative 4 
binding cavity calculation from CASTp program are colored light blue. Surface for 5 
residues that are not within binding cavity from ECL2 is not displayed. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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 1 
Figure 4. Predicted interactions between PAR2 and 2f-LIGRLO-NH2. (A) 2f-LIGRLO-2 
NH2 docked in ORL-1 derived PAR2 model; (B) 2f-LIGRLO-NH2 docked in PAR1 3 
derived PAR2 model. Green dotted boxes represent residues that display at least 10-fold 4 
loss in PAR2 activation upon mutation. This figure was generated using Ligplot53. 5 
 6 
Figure 5. Predicted interactions between PAR2 and agonist GB110. (A) GB110 docked 7 
in ORL-1-based PAR2 model; (B) GB110 docked in PAR1-based PAR2 model. Green 8 
 29 
dotted boxes represent residues that display at least 10-fold loss in PAR2 activation upon 1 
mutation. This figure was generated using Ligplot. 2 
 3 
Figure 6. Agonist and antagonist activity of 1 and 5 in HT29 cells. Concentration 4 
dependent Ca2+ release in HT29 cells induced by 1 (A) and 5 (B) at up to 100 µM (agonist 5 
assay) or inhibited by 1 and 5 in the presence of 1 µM 2f-LIGRLO-NH2 (antagonist 6 
assay). Normalized to 100% Ca2+ release for 100 µM 2f-LIGRLO-NH2. Panels reflect 7 
data for compounds in Table 4. Data are represented as mean ± SEM (n ≥ 3 independent 8 
experiments). 9 
 10 
 11 
 12 
Figure 7. Docked binding mode of compound 1 and 5 in ORL-1 and PAR1 based 13 
homology models of PAR2: (A) Compound 1 docked in ORL-1 based model. (B) 14 
Compound 5 docked in PAR1 based model. Hydrogen bond is depicted in red dashed 15 
line. Compounds are colored by atom types; carbon: green; oxygen: red; nitrogen: blue; 16 
sulfur: yellow.   17 
 18 
 30 
Table 1. Focused Similarity Comparison between PAR2 and Templates 
Template crystal 
structure 
TM % 
sequence 
identity 
TM % 
sequence 
similarity 
Ligand accessible 
site % sequence 
identity 
Ligand accessible site 
% sequence similarity 
Bovine Rhodopsin 21 42 11 39 
Human ORL-1 29 50 30 50 
Human PAR1 44 62 48 73 
 1 
 2 
 3 
 4 
 5 
Table 2. Validation of Homology Models 
Homology 
Models 
RMSD 
vs 
template 
Qmean6 
score DFIRE_energy 
% residues in 
favoured and 
allowed regions 
ERRAT 
score 
Rhodopsin_based 0.37 0.41 (0.49) -465.5 (-557.8) 100 81.5	
ORL-1_based 0.27 0.46 (0.5) -445.0 (-430.8) 99.2 83.6	
PAR1_based 0.09 0.42 (0.47) -463.09 (-492.4) 99.6 85.7 
Values within bracket are measured for the original template PDB structures. 6 
 7 
 8 
Table 3. Comparison of putative hotspot residues 
between PAR2 and 3 templates 
B.W. 
Number PAR2 PAR1 ORL-1 Rhodopsin 
3.32 F F D A 
3.33 Y Y Y T 
3.37 Y Y F E 
5.39 F F A V 
5.42 L F I M 
5.43 A S F F 
5.47 F F F F 
6.44 Y F F F 
6.51 S T V Y 
6.52 N N Q A 
6.55 L L V A 
6.59 Y Y G F 
7.35 Y Y L M 
7.39 L V T A 
 9 
 10 
 11 
 12 
Table 4. Structures and antagonist potencies of compounds 
derived from virtual screening in PAR2 homology models 
 31 
ID Structure IC50 (µM)a 
1 
 
11 ± 2 
2 
 
16 ± 4 
3 
 
41 ± 21 
4 
 
44 ± 20 
5 
 
30 ± 6 
6 
 
40 ± 9 
7 
 
93 ± 19 
8 
 
94 ± 30 
a Cell based Ca2+ mobilization in HT29 cells. Concentration dependent 1 
responses after 30 minutes pre-incubation then addition of agonist, 1 µM  2 
2f-LIGRLO-NH2.  Data are represented as mean ± SEM (n ≥ 3 independent  3 
experiments). Compounds 1-4 were derived from the ORL-1 based model 4 
 of PAR2; Compounds 5-8 were derived from the PAR1 based model of  5 
PAR2. 6 
 7 
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